SEARCH:   Advanced

Blood, 15 January 2007, Vol. 109, No. 2, pp. 486-491. Prepublished online as a Blood First Edition Paper on September 26, 2006; DOI 10.1182/blood-2005-11-006957. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2005-11-006957v1 109/2/486    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Schot, B. W. Articles by Vellenga, E. Search for Related Content PubMed PubMed Citation Articles by Schot, B. W. Articles by Vellenga, E. Related Collections Neoplasia Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma Bart W. Schot1, Josée M. Zijlstra3,4, Wim J. Sluiter1, Gustaaf W. van Imhoff1, Jan Pruim2, Willem Vaalburg2, and Edo Vellenga1, 1 Department of Hematology and 2 Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, The Netherlands; 3 Department of Hematology and 4 Department of Nuclear Medicine and PET Research, Vrije Universiteit (VU) University Medical Center, Amsterdam, The Netherlands This study was set up to demonstrate whether prognostic classification based on the secondary age-adjusted International Prognostic Index (sAA-IPI) for recurring aggressive non-Hodgkin lymphoma (NHL) or the prognostic score for recurring Hodgkin lymphoma (HL) can be improved by including the midtreatment results of fluorine-18-fluorodeoxy-glucose–positron emission tomography (FDG-PET). Clinical data on patients with recurring lymphoma who were treated with second-line chemotherapy (DHAP-VIM-DHAP) followed by autologous stem cell transplantation (ASCT) were collected and combined with the results of FDG-PET performed before and after 2 cycles of reinduction chemotherapy. PET responses after 2 courses were scored as complete remission (CR), partial remission (PR), or no response (NR). A multivariate analysis was performed to design a predictive model. The number of patients (101 of 117) included those (78 patients with aggressive NHL and 23 patients with HL) that could be analyzed according to protocol. Of these, 80 patients were chemosensitive and 77 received transplants. Both secondary clinical risk score (P < .001) and FDG-PET response (P < .001) were independent predictive factors for the total evaluable group of patients with lymphoma and for patients with NHL alone. The combined use of the clinical risk score and FDG-PET response after 2 chemotherapy courses identified at least 4 categories of patients with a failure-free survival varying between 5% to 100% after transplantation (P < .001). These data indicate that the secondary clinical risk score in conjunction with FDG-PET response provides a more accurate prognostic instrument for the outcome of second-line treatment at least in patients with recurring NHL. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: E. Vellenga, W. L. J. van Putten, M. B. van 't Veer, J. M. Zijlstra, W. E. Fibbe, M. H. J. van Oers, L. F. Verdonck, P. W. Wijermans, G. W. van Imhoff, P. J. Lugtenburg, et al. Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial Blood, January 15, 2008; 111(2): 537 - 543. [Abstract] [Full Text] [PDF] P. Seam, M. E. Juweid, and B. D. Cheson The role of FDG-PET scans in patients with lymphoma Blood, November 15, 2007; 110(10): 3507 - 3516. [Abstract] [Full Text] [PDF] N. A. Bakker and G. W. van Imhoff Post-transplant lymphoproliferative disorders: from treatment to early detection and prevention? Haematologica, November 1, 2007; 92(11): 1447 - 1450. [Full Text] [PDF] A. Gallamini, M. Hutchings, L. Rigacci, L. Specht, F. Merli, M. Hansen, C. Patti, A. Loft, F. Di Raimondo, F. D'Amore, et al. Early Interim 2-[18F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Is Prognostically Superior to International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: A Report From a Joint Italian-Danish Study J. Clin. Oncol., August 20, 2007; 25(24): 3746 - 3752. [Abstract] [Full Text] [PDF]

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020